FDA Grants Breakthrough Status to Izalontamab Brengitecan for EGFR-Mutant Lung Cancer
SystImmune Inc. and Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to izalontamab brengitecan…
Read More...
Read More...
